Stifel Financial Corp Decreases Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Stifel Financial Corp cut its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 1.8% in the third quarter, Holdings Channel.com reports. The institutional investor owned 5,321 shares of the medical research company’s stock after selling 95 shares during the quarter. Stifel Financial Corp’s holdings in Bio-Rad Laboratories were worth $1,780,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of BIO. UMB Bank n.a. raised its position in Bio-Rad Laboratories by 140.6% in the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock worth $26,000 after acquiring an additional 45 shares during the period. Capital Advisors Ltd. LLC increased its holdings in Bio-Rad Laboratories by 193.8% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock worth $26,000 after acquiring an additional 62 shares in the last quarter. Gladius Capital Management LP purchased a new stake in shares of Bio-Rad Laboratories in the third quarter worth $32,000. Point72 Hong Kong Ltd bought a new position in Bio-Rad Laboratories in the 3rd quarter worth $55,000. Finally, Headlands Technologies LLC bought a new position in shares of Bio-Rad Laboratories in the second quarter worth about $51,000. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Performance

Bio-Rad Laboratories stock opened at $327.47 on Friday. Bio-Rad Laboratories, Inc. has a 1-year low of $262.12 and a 1-year high of $387.99. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.14 and a quick ratio of 4.52. The firm has a market capitalization of $9.17 billion, a P/E ratio of -11.98 and a beta of 0.90. The company’s 50-day moving average is $340.91 and its 200 day moving average is $322.11.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.16 by $0.85. The company had revenue of $649.70 million for the quarter, compared to the consensus estimate of $628.18 million. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The firm’s revenue was up 2.8% compared to the same quarter last year. During the same quarter last year, the firm posted $2.33 EPS. Research analysts forecast that Bio-Rad Laboratories, Inc. will post 10.29 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on BIO. Wells Fargo & Company started coverage on shares of Bio-Rad Laboratories in a report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 price objective for the company. StockNews.com raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Citigroup lifted their price objective on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, Royal Bank of Canada increased their price objective on shares of Bio-Rad Laboratories from $369.00 to $481.00 and gave the company an “outperform” rating in a research report on Monday, December 9th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $394.20.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.